Daily Archives: January 5, 2017

Amorsa Therapeutics Announces Strategic Collaboration Facilitated by Johnson & Johnson Innovation to Develop New Therapy for Treatment-­‐Resistant Depression

Southborough, MA, January 5, 2017 – Amorsa Therapeutics, Inc., a neuropharmaceutical company pioneering the development of breakthrough treatments for nervous system disorders has announced a research, option and license agreement with Janssen Pharmaceuticals, Inc. to develop and commercialize a novel small molecule drug candidate for treatment-resistant depression based on Amorsa’s proprietary ketamine analog technology. Amorsa’s product candidates are designed to show efficacy as rapidly acting antidepressants with an extended duration of action, possess an attractive side-effect profile, and enable oral dose administration. Under the terms of the agreement, facilitated by Johnson & Johnson Innovation, Amorsa will receive an upfront payment, More